Tethering ATG16L1 or LC3 induces targeted autophagic degradation of protein aggregates and mitochondria

Mei, Ligang; Chen, Xiaorong; Wei, Fujing; Huang, Xue; Lu, Lan; Yao, Jia; Jing, Chunxia; Luo, Xunguang; Wang, Z; Yang, Aimin

doi:10.1080/15548627.2023.2234797

Cited by 15 publications

(1 citation statement)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To explore the association between m 1 A modification and autophagy in HCC by culturing HepG2 cells and QGY cells in Earle’s balanced salt solution (EBSS) for 6 and 12 h to generate an autophagy model of HCC cells (Fig. 5 A) [ 28 ]. Notably, cell proliferation significantly decreased upon induced autophagy (Fig.…”

Section: Resultsmentioning

confidence: 99%

m1A regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma

Wu,

Li,

Wang

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background N1-methyladenosine (m1A), among the most common internal modifications on RNAs, has a crucial role to play in cancer development. The purpose of this study were systematically investigate the modification characteristics of m1A in hepatocellular carcinoma (HCC) to unveil its potential as an anticancer target and to develop a model related to m1A modification characteristics with biological functions. This model could predict the prognosis for patients with HCC. Methods An integrated analysis of the TCGA-LIHC database was performed to explore the gene signatures and clinical relevance of 10 m1A regulators. Furthermore, the biological pathways regulated by m1A modification patterns were investigated. The risk model was established using the genes that showed differential expression (DEGs) between various m1A modification patterns and autophagy clusters. These in vitro experiments were subsequently designed to validate the role of m1A in HCC cell growth and autophagy. Immunohistochemistry was employed to assess m1A levels and the expression of DEGs from the risk model in HCC tissues and paracancer tissues using tissue microarray. Results The risk model, constructed from five DEGs (CDK5R2, TRIM36, DCAF8L, CYP26B, and PAGE1), exhibited significant prognostic value in predicting survival rates among individuals with HCC. Moreover, HCC tissues showed decreased levels of m1A compared to paracancer tissues. Furthermore, the low m1A level group indicated a poorer clinical outcome for patients with HCC. Additionally, m1A modification may positively influence autophagy regulation, thereby inhibiting HCC cells proliferation under nutrient deficiency conditions. Conclusions The risk model, comprising m1A regulators correlated with autophagy and constructed from five DEGs, could be instrumental in predicting HCC prognosis. The reduced level of m1A may represent a potential target for anti-HCC strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

m1A regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma

Wu,

Li,

Wang

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF‐2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma

Zhu,

Li,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Immune checkpoint blockers (ICBs) therapy stands as the first‐line treatment option for advanced renal cell carcinoma (RCC). However, its effectiveness is hindered by the immunosuppressive tumor microenvironment (TME). Sonodynamic therapy (SDT) generates tumor cell fragments that can prime the host's antitumor immunity. Nevertheless, the hypoxic microenvironment and upregulated autophagy following SDT often lead to cancer cell resistance. In response to these challenges, a hypoxia‐responsive polymer (Poly(4,4′‐azobisbenzenemethanol‐PMDA)‐mPEG5k, P‐APm) encapsulating both a HIF‐2α inhibitor (belzutifan) and the ultrasonic sensitize (Chlorin e6, Ce6) is designed, to create the nanoparticle APm/Ce6/HIF. APm/Ce6/HIF combined with ultrasound (US) significantly suppresses tumor growth and activates antitumor immunity in vivo. Moreover, this treatment effectively transforms the immunosuppressive microenvironment from “immune‐cold” to “immune‐hot”, thereby enhancing the response to ICBs therapy. The findings indicate that APm/Ce6/HIF offers a synergistic approach combining targeted therapy with immunotherapy, providing new possibilities for treating RCC.

show abstract

Targeting autophagy with pharmacological small molecules to treat human diseases

Wang,

Fu,

Liu

2025

Drug Discovery Stories

View full text Add to dashboard Cite

Tethering ATG16L1 or LC3 induces targeted autophagic degradation of protein aggregates and mitochondria

Cited by 15 publications

References 88 publications

m1A regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma

m1A regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma

Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF‐2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma

Targeting autophagy with pharmacological small molecules to treat human diseases

Contact Info

Product

Resources

About